# EDGAR Filing Document

**Accession Number:** 0001540159
**File Stem:** 0001654954-23-002689
**Filing Date:** 2023-3
**Character Count:** 4788
**Document Hash:** 6f810fb893633344c979f1d4118bc6e3
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001654954-23-002689.hdr.sgml**: 20230313

**ACCESSION NUMBER**: 0001654954-23-002689

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20230313

**ITEM INFORMATION**: Regulation FD Disclosure

**FILED AS OF DATE**: 20230313

**DATE AS OF CHANGE**: 20230313

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Edesa Biotech, Inc.
- **CENTRAL INDEX KEY:** 0001540159
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37619
- **FILM NUMBER:** 23725943

**BUSINESS ADDRESS:**
- **STREET 1:** 100 SPY COURT
- **CITY:** MARKHAM
- **STATE:** A6
- **ZIP:** L3R 5H6
- **BUSINESS PHONE:** (905) 475-1234

**MAIL ADDRESS:**
- **STREET 1:** 100 SPY COURT
- **CITY:** MARKHAM
- **STATE:** A6
- **ZIP:** L3R 5H6

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Stellar Biotechnologies, Inc.
- **DATE OF NAME CHANGE:** 20120120

?xml version="1.0" encoding="utf-8"?edsa_8k.htm

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT** 

**PURSUANT TO SECTION 13 OR 15(d) OF** 

**THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported): March 13, 2023** 

---

| |
|:---|
| **Edesa Biotech, Inc.** |
| **(Exact Name of Registrant as Specified in its Charter)**  |

---

---

| | | |
|:---|:---|:---|
| **British Columbia, Canada** | **001-37619** | **N/A** |
| (State or Other Jurisdiction<br>of Incorporation) | (Commission<br>File Number) | (IRS Employer<br>Identification No.) |
| **100 Spy Court**<br>**<u>Markham, Ontario, Canada L3R 5H6</u>** | **100 Spy Court**<br>**<u>Markham, Ontario, Canada L3R 5H6</u>** | **100 Spy Court**<br>**<u>Markham, Ontario, Canada L3R 5H6</u>** |
| (Address of Principal Executive Offices) | (Address of Principal Executive Offices) | (Address of Principal Executive Offices) |

---

<u>**(289) 800-9600**</u>

Registrant's telephone number, including area code

<u>**N/A**</u>

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<u>see</u> General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of exchange on which registered** |
| Common Shares | EDSA | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

---

| | |
|:---|:---|
| **Item 7.01** | **Regulation FD Disclosure.** |

---

Edesa Biotech, Inc. (the "Company") is aware that the Federal Deposit Insurance Corp. (FDIC) has taken control of Silicon Valley Bank due to liquidity concerns. The Company does not hold deposits or securities at Silicon Valley Bank.

The information in this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the Exchange Act) or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

2<br>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | Edesa Biotech, Inc. | Edesa Biotech, Inc. |
| Date: March 13, 2023 | By: | */s/ Michael Brooks* |
|  | Name:  | Michael Brooks |
|  | Title: | President |

---

3<br>